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Glycogen storage disease type Ib (GSD Ib) [MIM 232220] 
is caused by mutations in the gene encoding microsomal 
glucose-6-phosphate translocase (G6PT) (Veiga-Da-
Cunha et al, 1998). This solute carrier family 37, member 
4 gene (SLC37A4) is located on chromosome 11q23.3 and 
encodes a 429 amino acid polypeptide (Veiga-Da-Cunha 
et al, 1998). This protein transports glucose-6-phosphate 
into the endoplasmic reticulum, where the enzyme 
glucose-6-phosphatase converts glucose-6-phosphate into 
glucose and inorganic phosphate. Mutations in SLC37A4 
result in accumulation of glucose-6-phosphate in cells. The 
SLC37A4 gene has 9 exons and so far 83 mutations have 
been reported (Human Gene Mutation Database, 2011). 
Here, we report the identification of a novel mutation in 
the SLC37A4 gene in a Sri Lankan child and the associated 
clinical phenotype.  
 
This child was a three month old baby boy – the first child 
born to a consanguineous Sinhalese couple. The child had 
had pyrexia and umbilical sepsis few days after birth and 
recurrent, generalized pustular skin eruptions on and off 
since then. His abdomen was protruding. He had had 
persistent neutropenia, confirmed by haematological tests 
from the age of 3 weeks. Physical examination showed a 
grossly enlarged liver. He weighed 5.8Kg (Birth weight: 
3.6Kg). The weight was within the 50th percentile.  
 
Investigation findings were as follows: Fasting blood 
glucose: 66mg/dl (reference interval: 65-110mg/dl); 
plasma lactate: 89.8mg/dl (reference interval: 4.5-
19.8mg/dl); serum uric acid: 8.54mg/dl (reference interval: 
2.4-7.0mg/dl); serum triglycerides: 1236mg/dl (reference 
interval: 10 -200mg/dl); serum cholesterol: 242mg/dl 
(reference interval: 140-239 mg/dl); Analyne transaminase 
(ALT): 225.3U/l (reference interval: <40U/l); Aspartate 
transaminase (AST): 566.5U/l (reference interval: <40U/l), 
Alkaline phosphetase: 795.5U/l (reference interval: 98-
279U/l) and Gamma glutaryl transferase: 960.1U/l 
(reference interval: 7-50U/l). 
 
The neutrophil count in the peripheral blood was 
frequently fluctuating between 0.2×103/μl and 0.9×103/μl 
(reference interval: 1.5-9.0×103/μl) throughout this period. 
Bone marrow biopsy and peripheral blood picture were 
otherwise normal except for the low neutrophil counts. 
Based on the above clinical and laboratory findings, a 
clinical diagnosis of GSD type I was determined. First 
mutation analysis of the glucose-6-phosphatase (G6PC) 
gene was undertaken to confirm/exclude GSD Ia. No 
mutations were found in the G6PC  gene. This was 
followed by screening for mutations in SLC37A4 gene to 
confirm/exclude GSD Ib. Genetic testing in both instances 
was done after obtaining written informed consent from 
the parents. Genomic DNA was extracted from the child’s 
peripheral venous blood. All the exons and intron-exon 
boundaries of the G6PC  and  SLC37A4  genes were 
analyzed. Direct sequencing of PCR products was 
performed on both forward and reverse strands using the 
same primers for PCR. Cycle sequencing was performed 
with a BigDye Terminator Cycle Sequencing Ready 
Reaction kit (Applied Biosystems, Foster City, CA, USA). 
The sequence was read following capillary electrophoresis 
on an ABI 3130 Genetic Analyzer (Applied Biosystems). 
The sequence was compared with the reference sequence 
(NG_013331.1 RefSeqGene) in the National Center for 
Biotechnology Information database 
(http://www.ncbi.nlm.nih.gov). Detailed methods can be 
provided on request.  
 
Sequence analysis showed that codon 50 of the SLC37A4 
gene was converted from GGG to GAG by the substitution 
of a Guanine nucleotide by an Adenine nucleotide (Figure 1). 263 
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This results in the substitution of Glyceine (G) by Glutemic 
acid (E) in the amino acid sequence of the G6PT protein 
[p.G50E].  
 
GSD type I or von Gierke disease includes a clinically, 
biochemically, and genetically heterogeneous group of 
autosomal recessive disorders. The basic defects reside in 
the impairment of the terminal steps of glycogenolysis and 
gluconeogenesis, at different levels. Mutations of the G6PC 
gene are responsible for the most frequent form of GSD 
type I, the subtype Ia. In GSD Ia, the white blood cell count 
is generally within reference ranges because leukocyte 
function is unaffected by the defect. In contrast, chronic 
neutropenia due to impaired function of neutrophils, is 
found in GSD Ib (Visser et al, 2000). The clinical 
manifestations of GSD type I include growth retardation, 
hepatomegaly, hypoglycemia, lactic acidemia, 
hyperuricemia, and hyperlipidemia. In addition, patients 
with GSD Ib commonly have infectious complications 
which are caused by neutropenia and dysfunction of 
neutrophils. The diagnosis of GSD type I is based on its 
clinical presentation; i.e., abnormal plasma concentrations 
of glucose, lactate, uric acid, triglycerides, lipids; liver 
biopsy to measure enzyme activity; and molecular genetic 
testing (Visser et al, 2000). 
 
This child had all the clinical and biochemical parameters 
suggestive of GSD Ia, except persistent neutropenia. 
Individuals with GSD Ia who are homozygous for the 
p.G188R mutation in the G6PC gene have been reported 
with GSD Ib like phenotype with neutropaenia (Weston et 
al, 2000). This child was tested for mutations in the G6PC 
gene to exclude this possibility. In untreated patients with 
GSD Ib, neutropenia usually manifests after about 1 year of 
age (Weston et al, 2000). In this child however, neutrophils 
were significantly reduced, with recurrent skin sepsis almost 
from birth.  
 
In summary, we identified a missence mutation in the 
SLC37A4 gene [p.G50E] in a Sri Lankan child with clinical 
and laboratory findings suggestive of the diagnosis of GSD 
Ib. This is a new mutation which has not been described 
before in other children with GSD Ib and it appears that it is 
associated with very early onset neutorpaenia.  
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Figure 1. Electrophorogram of the sense strand nucleotide sequence of the SLC37A4 gene. The arrow indicates 
Guanine Æ Adenine substitution at codon 50 in exon 1, resulting in the p.G50E missense mutation.  